Axon Enterprise, Inc $AXON Stock Position Cut by Strategy Capital LLC

Strategy Capital LLC lessened its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 0.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 431,577 shares of the biotechnology company’s stock after selling 1,087 shares during the quarter. Axon Enterprise makes up 20.5% of Strategy Capital LLC’s holdings, making the stock its biggest position. Strategy Capital LLC owned about 0.55% of Axon Enterprise worth $309,717,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in shares of Axon Enterprise during the 4th quarter valued at about $480,000. NewEdge Advisors LLC raised its holdings in Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock worth $1,207,000 after purchasing an additional 668 shares during the period. Empowered Funds LLC raised its holdings in Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 157 shares during the period. Woodline Partners LP boosted its position in Axon Enterprise by 40.6% during the first quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock worth $3,646,000 after purchasing an additional 2,003 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in Axon Enterprise during the second quarter worth approximately $284,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock opened at $574.01 on Monday. The stock has a market capitalization of $46.15 billion, a P/E ratio of 377.64, a PEG ratio of 12.25 and a beta of 1.46. The business has a 50 day simple moving average of $536.08 and a two-hundred day simple moving average of $616.86. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million for the quarter, compared to analyst estimates of $755.29 million. During the same period in the previous year, the company posted $2.08 earnings per share. The business’s revenue was up 38.5% on a year-over-year basis. As a group, analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the transaction, the insider directly owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This trade represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Jennifer H. Mak sold 1,500 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $573.45, for a total transaction of $860,175.00. Following the transaction, the chief accounting officer owned 12,240 shares in the company, valued at $7,019,028. The trade was a 10.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 26,634 shares of company stock worth $14,963,095. Company insiders own 5.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on AXON shares. Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Barclays cut their price target on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Royal Bank Of Canada reduced their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. Finally, Morgan Stanley decreased their price objective on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.